<DOC>
	<DOCNO>NCT01697839</DOCNO>
	<brief_summary>This prospective study investigate relationship vitamin D peripheral neuropathy ( PN ) among multiple myeloma ( MM ) patient treat either bortezomib thalidomide . The study consist screen period 14 day , follow single assessment visit evaluate vitamin D level , incidence severity PN , neuropathic pain , marker depression . Patient chart also utilized assess frequency skeletal-related event .</brief_summary>
	<brief_title>Serum Vitamin D Levels Peripheral Neuropathy Among Multiple Myeloma Patients</brief_title>
	<detailed_description>Approximately 10 % myeloma patient present diagnosis clinical neuropathy although study reveal many 1/3 may abnormal electrophysiological examination . Baseline neuropathic abnormal finding exacerbate many myeloma treatment , especially bortezomib , thalidomide , less extent lenalidomide . Several study suggest vitamin D supplementation may help reduce symptom neuropathy.In prospective study , investigate relationship vitamin D PN among MM patient treat either bortezomib thalidomide . The study consist screen period 14 day , follow single assessment visit evaluate vitamin D level , incidence severity PN , neuropathic pain , marker depression . Patient chart also utilized assess frequency skeletal-related event .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Prior diagnosis multiple myeloma base standard criterion ( Durie 1986 ) Received consecutive , prior treatment MM regimen consist least 16 consecutive week bortezomib 16 consecutive week thalidomide prior Day Assessment The 16 week consecutive treatment must include least one follow dos schedule : Bortezomib : ≥ 1.0 mg/m² dose 3 time per 4week period Thalidomide : ≥ 50 mg/day dose daily The qualify regimen may include bortezomib thalidomide . However , inclusion requirement need satisfy either one agent . Age ≥18 year time signing informed consent form Able adhere study visit schedule protocol requirement Plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ( POEMS ) syndrome ( Bardwick 1980 ) Plasma cell leukemia Primary amyloidosis Vitamin D level assessment occur within 12 month precede Day Assessment Vitamin D nondietary oral supplementation &gt; 1200 IU per day &gt; 30 total day within 12 month period precede Day Assessment Serious medical psychiatric illness likely interfere participation clinical study . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>